洁特生物(688026) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥130,039,526.89, a decrease of 15.87% compared to the same period last year[3]. - Total profit for the quarter was ¥12,494,752.97, down 48.16% year-on-year[3]. - Net profit attributable to shareholders was ¥10,952,688.00, reflecting a decline of 45.66% compared to the previous year[3]. - The basic earnings per share for the quarter was ¥0.08, a decrease of 55.56% year-on-year[3]. - Total operating revenue for the first three quarters of 2025 reached ¥398,180,432.24, a slight increase from ¥390,816,368.30 in the same period of 2024, representing a growth of approximately 0.93%[19]. - The net profit for the first three quarters of 2025 reached ¥58,625,749.54, an increase of 16.5% compared to ¥50,337,922.51 in the same period of 2024[20]. - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.42, slightly up from ¥0.41 in the same period of 2024[20]. Research and Development - Research and development expenses totaled ¥7,784,426.48, accounting for 5.99% of operating revenue, an increase of 1.75 percentage points[4]. - Research and development expenses increased to ¥21,096,099.18 in 2025 from ¥19,834,731.06 in 2024, marking an increase of about 6.4%[19]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥128,296,599.37, a significant increase of 1,268.59% compared to the previous year[3]. - Cash and cash equivalents as of September 30, 2025, amounted to ¥438,226,897.19, up from ¥284,205,896.01 at the end of 2024, representing a growth of approximately 54.3%[14]. - Total assets at the end of the reporting period were ¥1,748,226,296.50, representing a 2.71% increase from the end of the previous year[4]. - Total assets as of September 30, 2025, were ¥1,748,226,296.50, compared to ¥1,702,023,099.33 at the end of 2024, showing an increase of approximately 2.7%[15]. - The company's retained earnings increased to ¥513,013,576.86 in 2025 from ¥465,769,398.40 in 2024, reflecting a growth of approximately 10.1%[16]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,274[9]. - The largest shareholder, Yuan Jianhua, holds 41,072,020 shares, representing 29.26% of total shares[9]. - JET (H.K.) BIOSCIENCE holds 17,547,293 shares, accounting for 12.50% of total shares[9]. - The company has a total of 10 major shareholders, with the top 10 holding significant stakes in the company[10]. Legal Matters - The company is involved in a lawsuit with Shanghai You Electronic Technology Co., Ltd. regarding a contract dispute, with a claim amount of RMB 18,441,691.80 and a penalty of RMB 1,386,000[11]. - The court ruled that Shanghai You must return RMB 11,256,957.82 to the company and pay a penalty of RMB 922,084.59[11]. - The company is also in a legal dispute with Shenzhen Hesheng Medical Technology Co., Ltd. over a mold procurement contract, with a claim amount of RMB 10,340,829.00 and damages of RMB 644,911[12]. - The court ordered Hesheng Medical to return the claimed amount and compensate for damages, but Hesheng Medical has appealed the decision[12]. - The company has had part of its funds frozen amounting to RMB 11,473,149.78 due to ongoing litigation[13]. - The company is actively managing its legal disputes to mitigate financial impacts and protect shareholder interests[11]. Operating Costs - Total operating costs for the first three quarters of 2025 were ¥340,567,157.86, compared to ¥329,050,630.04 in 2024, indicating an increase of about 3.8%[19]. - The total cash outflow from operating activities in the first three quarters of 2025 was ¥392,674,512.47, a decrease from ¥423,922,874.13 in the same period of 2024[22].